Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Primary Health Care | 3 | 2010 | 339 | 0.620 |
Why?
|
| Confidentiality | 1 | 2010 | 78 | 0.380 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 106 | 0.350 |
Why?
|
| Abortion, Induced | 2 | 2010 | 120 | 0.340 |
Why?
|
| Attitude to Health | 2 | 2008 | 220 | 0.310 |
Why?
|
| Prostatic Neoplasms | 9 | 1995 | 1721 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 1992 | 176 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 508 | 0.120 |
Why?
|
| Aging | 2 | 2009 | 691 | 0.120 |
Why?
|
| Radiosurgery | 1 | 1996 | 272 | 0.110 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 67 | 0.110 |
Why?
|
| New York City | 2 | 2010 | 59 | 0.100 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 218 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 103 | 0.100 |
Why?
|
| Disclosure | 2 | 2010 | 108 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 1992 | 177 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1991 | 157 | 0.090 |
Why?
|
| Focus Groups | 1 | 2010 | 155 | 0.090 |
Why?
|
| Vitamin D | 1 | 2012 | 261 | 0.090 |
Why?
|
| Telomere Shortening | 1 | 2009 | 23 | 0.090 |
Why?
|
| Mothers | 1 | 2010 | 141 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2010 | 148 | 0.090 |
Why?
|
| Mortality | 2 | 2009 | 149 | 0.090 |
Why?
|
| Telomere | 1 | 2009 | 108 | 0.090 |
Why?
|
| Patient Preference | 1 | 2010 | 105 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2010 | 160 | 0.080 |
Why?
|
| Leg | 1 | 2009 | 137 | 0.080 |
Why?
|
| Urban Health | 1 | 2008 | 55 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2009 | 236 | 0.080 |
Why?
|
| Adolescent | 3 | 2010 | 8981 | 0.080 |
Why?
|
| Supine Position | 2 | 1997 | 30 | 0.080 |
Why?
|
| Health | 1 | 2006 | 29 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 327 | 0.070 |
Why?
|
| Body Composition | 1 | 2006 | 68 | 0.070 |
Why?
|
| Aged | 10 | 2012 | 18415 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 610 | 0.070 |
Why?
|
| Cognition | 1 | 2009 | 570 | 0.060 |
Why?
|
| Humans | 25 | 2012 | 86643 | 0.060 |
Why?
|
| Female | 12 | 2012 | 44532 | 0.060 |
Why?
|
| Pregnancy | 2 | 2010 | 2894 | 0.060 |
Why?
|
| Middle Aged | 9 | 2010 | 25028 | 0.060 |
Why?
|
| Adult | 7 | 2010 | 25648 | 0.060 |
Why?
|
| Male | 16 | 2012 | 40965 | 0.060 |
Why?
|
| Radiotherapy Dosage | 5 | 1995 | 468 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2012 | 4213 | 0.050 |
Why?
|
| Posture | 2 | 2009 | 125 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2008 | 2501 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2009 | 3640 | 0.050 |
Why?
|
| Equipment Design | 2 | 1997 | 406 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2012 | 6509 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5976 | 0.040 |
Why?
|
| Computer Terminals | 1 | 1997 | 7 | 0.040 |
Why?
|
| Immobilization | 1 | 1997 | 22 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 1992 | 533 | 0.040 |
Why?
|
| Restraint, Physical | 1 | 1996 | 27 | 0.040 |
Why?
|
| Subtraction Technique | 1 | 1997 | 133 | 0.040 |
Why?
|
| Technology, Radiologic | 1 | 1996 | 103 | 0.030 |
Why?
|
| Neutrons | 1 | 1995 | 58 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 1993 | 1169 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1995 | 69 | 0.030 |
Why?
|
| Photons | 1 | 1995 | 46 | 0.030 |
Why?
|
| Cause of Death | 2 | 2012 | 277 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 1993 | 2601 | 0.030 |
Why?
|
| Extremities | 1 | 1995 | 167 | 0.030 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 1993 | 25 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 286 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1995 | 255 | 0.030 |
Why?
|
| Sarcoma | 1 | 1995 | 215 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1993 | 49 | 0.030 |
Why?
|
| Erythropoietin | 1 | 1993 | 91 | 0.030 |
Why?
|
| Tennessee | 1 | 2012 | 17 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2012 | 75 | 0.030 |
Why?
|
| Anemia | 1 | 1993 | 128 | 0.030 |
Why?
|
| Urethra | 1 | 1993 | 113 | 0.030 |
Why?
|
| Carcinoma | 1 | 1995 | 436 | 0.030 |
Why?
|
| Mediastinum | 1 | 1992 | 46 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 683 | 0.030 |
Why?
|
| Radiometry | 1 | 1992 | 53 | 0.030 |
Why?
|
| Chromatography, Paper | 1 | 1991 | 11 | 0.020 |
Why?
|
| Coitus | 1 | 1991 | 20 | 0.020 |
Why?
|
| Value of Life | 1 | 1991 | 22 | 0.020 |
Why?
|
| Social Values | 1 | 1991 | 44 | 0.020 |
Why?
|
| Genes, Retinoblastoma | 1 | 1991 | 22 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 2767 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1991 | 87 | 0.020 |
Why?
|
| Treatment Failure | 3 | 1995 | 285 | 0.020 |
Why?
|
| Vulva | 1 | 1990 | 23 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 1994 | 2903 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 1990 | 20 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1991 | 265 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 763 | 0.020 |
Why?
|
| Combined Modality Therapy | 4 | 1995 | 1686 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2009 | 19 | 0.020 |
Why?
|
| Postural Balance | 1 | 2009 | 42 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1991 | 1041 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 2 | 1997 | 1052 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1991 | 927 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 502 | 0.020 |
Why?
|
| Base Sequence | 1 | 1991 | 2330 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1991 | 3030 | 0.020 |
Why?
|
| Educational Status | 1 | 2006 | 188 | 0.020 |
Why?
|
| Chicago | 1 | 2010 | 1379 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1991 | 1981 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 2438 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1991 | 0.020 |
Why?
|
| Health Status | 1 | 2006 | 360 | 0.020 |
Why?
|
| Hospitalization | 1 | 2009 | 849 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1990 | 1076 | 0.010 |
Why?
|
| Quality of Life | 1 | 1991 | 1585 | 0.010 |
Why?
|
| Methods | 2 | 1993 | 152 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 1995 | 1204 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1995 | 1014 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1995 | 1961 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 2262 | 0.010 |
Why?
|
| Neoplasms | 1 | 1995 | 2898 | 0.010 |
Why?
|
| Mutation | 1 | 1991 | 3968 | 0.010 |
Why?
|
| Computer Simulation | 2 | 1993 | 1078 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 66 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5417 | 0.010 |
Why?
|
| Radiobiology | 1 | 1995 | 13 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1995 | 188 | 0.010 |
Why?
|
| Vincristine | 1 | 1994 | 111 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1994 | 68 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 292 | 0.010 |
Why?
|
| Methotrexate | 1 | 1994 | 249 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 299 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 295 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 117 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1995 | 328 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1994 | 556 | 0.010 |
Why?
|
| Cisplatin | 1 | 1994 | 612 | 0.010 |
Why?
|
| Radiography | 1 | 1993 | 813 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 826 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 274 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 1939 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 1056 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1995 | 8489 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1990 | 155 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1990 | 397 | 0.000 |
Why?
|
| Survival Rate | 1 | 1991 | 1863 | 0.000 |
Why?
|
| Risk Assessment | 1 | 1991 | 2261 | 0.000 |
Why?
|